Nephrotic Syndrome

SAN DIEGO — Pegcetacoplan may offer a clinical strategy to stabilize kidney function and reduce proteinuria significantly for patients with C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis, data show.

Incident cardiovascular and thromboembolic events may be more closely linked to the severity of kidney disease than with glomerular disease subtype, according to results of a prospective study.

Mycophenolate mofetil may be a viable alternative to steroids for induction therapy in children with steroid-sensitive idiopathic nephrotic syndrome, researchers found in a study.

Among patients with focal segmental glomerulosclerosis, immunosuppressant therapy reduced proteinuria but showed no certain impact on kidney function.

The presence of anti-rituximab antibodies does not change the response that pediatric patients with steroid-dependent nephrotic syndrome have to rituximab treatment, according to a speaker from ASN Kidney Week.

Prolonged initial prednisolone therapy does not significantly alter the disease course in young children with nephrotic syndrome, according to a speaker at ASN Kidney Week.

Compared with a cohort free of kidney disease, patients with primary nephrotic syndrome were nearly 20-times more likely to develop kidney failure within 4.5 years of follow-up, research showed.

Use of NSAIDs was associated with a greater risk for nephrotic syndrome after at least 2 weeks of exposure, according to a recently published study.